Verve Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Eli Lilly and Company has successfully completed its tender offer and subsequent merger to acquire Verve Therapeutics, Inc., making Verve a wholly-owned subsidiary.
8-K: Verve Therapeutics Establishes Executive Retention Program Amidst Pending Eli Lilly Acquisition
Verve Therapeutics, Inc. has implemented a retention bonus program for its Chief Financial Officer and Chief Operating Officer/General Counsel, totaling over $900,000, as the company progresses towards its acquisition by Eli Lilly and Company.
Eli Lilly and Company has announced a definitive agreement to acquire Verve Therapeutics, a clinical-stage gene editing company, for an upfront cash payment of $10.50 per share plus a contingent value right of up to $3.00 per share.
Verve Therapeutics, Inc. announced that its stockholders approved all three proposals at the Annual Meeting held on June 5, 2025, including the election of Class I directors, ratification of Ernst & Young LLP as auditor, and advisory approval of executive compensation.
Verve Therapeutics announces positive initial data from its Heart-2 Phase 1b clinical trial of VERVE-102, demonstrating dose-dependent LDL-C reductions, and reports a cash runway into mid-2027.
Verve Therapeutics reports positive initial safety and efficacy data from its Heart-2 Phase 1b clinical trial of VERVE-102, showing dose-dependent reductions in LDL-C in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease.
8-K: Verve Therapeutics Announces Positive Pipeline Progress and Reports Year-End 2024 Financial Results
Verve Therapeutics reports pipeline advancements, including upcoming data releases for VERVE-102 and VERVE-201, and a strong cash position extending into mid-2027.
Verve Therapeutics announced pipeline advancements, including the dosing of participants in two clinical trials, and reported its third quarter 2024 financial results, highlighting a strong cash position.
Verve Therapeutics announced pipeline advancements, including progress in the Heart-2 clinical trial and plans for VERVE-201, alongside its second quarter 2024 financial results.
Verve Therapeutics has appointed Jodie Morrison and Ourania Nia Tatsis to its board of directors, increasing its size to nine members.
Verve Therapeutics has updated its previous 8-K filing to reflect the outcome of a non-binding advisory vote at its annual meeting, where a majority favored annual votes on executive compensation.
Verve Therapeutics held its annual meeting on June 6, 2024, where stockholders elected directors, ratified the accounting firm, and voted on executive compensation matters.
Verve Therapeutics has appointed Troy Lister as its new Chief Scientific Officer, succeeding Andrew Bellinger who will transition to an advisory role.
Verve Therapeutics announced its first quarter 2024 financial results, highlighted by the first patient dosed in the Heart-2 trial for VERVE-102 and progress on other gene editing programs.
8-K: Verve Therapeutics Pauses VERVE-101 Trial Enrollment After Adverse Event, Prioritizes VERVE-102
Verve Therapeutics has paused enrollment in its Heart-1 trial for VERVE-101 due to a patient experiencing transient laboratory abnormalities, while also announcing regulatory clearance for its Heart-2 trial of VERVE-102.
Verve Therapeutics announced positive interim data from its Heart-1 trial, progress in its pipeline, and a strong cash position to fund operations into late 2026.